Abstract
The global CAPItello-291 phase 3 study demonstrated that the AKT inhibitor capivasertib, combined with fulvestrant, significantly improves progression-free survival (PFS) in patients with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer. This paper details the findings from the Chinese cohort (n=134), confirming that the benefit-risk profile remains favorable in this population. Capivasertib-fulvestrant more than doubled median PFS in the overall population and across genetic subgroups, regardless of PIK3CA/AKT1/PTEN alterations.
Introduction
HR+/HER2- breast cancer is the most prevalent subtype globally. While endocrine therapy combined with CDK4/6 inhibitors is the standard first-line treatment, resistance inevitably develops. Standard second-line monotherapies often yield poor outcomes, with median PFS typically ranging between 2 and 4 months. The PI3K/AKT/PTEN signaling pathway is a key driver of this resistance. Capivasertib, a potent AKT inhibitor, aims to overcome this by targeting a central node in the escape pathway.
Methods
This prespecified exploratory analysis included 134 Chinese patients (24 from the global study and 110 from an extended cohort). Patients with HR+/HER2- advanced breast cancer that progressed during or after aromatase inhibitor therapy were randomized 1:1 to receive capivasertib (400 mg twice daily, 4 days on/3 days off) plus fulvestrant, or placebo plus fulvestrant. Tumors were stratified by the presence of PIK3CA/AKT1/PTEN alterations using Next-Generation Sequencing (NGS). The primary endpoint was investigator-assessed PFS.
Key Results
The addition of capivasertib to fulvestrant provided a statistically significant and clinically meaningful improvement in PFS across the Chinese cohort.
- Overall Population: Median PFS increased from 2.8 months with placebo to 6.9 months with capivasertib (Hazard Ratio [HR] 0.51; 95% CI 0.34–0.76).
- Altered Tumors: In patients with PIK3CA/AKT1/PTEN alterations, median PFS was 5.7 months vs. 1.9 months (HR 0.41; 95% CI 0.19–0.85).
- Non-Altered Tumors: Notably, patients without these alterations also saw substantial benefit, with a median PFS of 9.2 months vs. 2.7 months (HR 0.38; 95% CI 0.21–0.68).
Subgroup Consistency
The benefit of capivasertib was consistent across various clinical subgroups, including age, menopausal status, and the presence of liver or visceral metastases. This consistency underscores the robustness of AKT inhibition as a therapeutic strategy in this patient population, despite differences in regional treatment patterns such as lower prior use of CDK4/6 inhibitors compared to Western cohorts.
Safety and Tolerability
The safety profile in the Chinese cohort was consistent with the global CAPItello-291 study. The most frequent adverse events (AEs) with capivasertib-fulvestrant were diarrhea (60.6%) and hyperglycemia (57.7%). Most AEs were low-grade and manageable through dose interruptions or standard supportive care. Discontinuation due to AEs occurred in 11.3% of the capivasertib group compared to 3.2% in the placebo group.
Discussion and Future Directions
The CAPItello-291 Chinese cohort study confirms that capivasertib plus fulvestrant is an effective second-line option for HR+/HER2- advanced breast cancer. The significant benefit observed in patients with "non-altered" tumors is particularly intriguing, suggesting that AKT pathway activation may occur through mechanisms not captured by DNA sequencing alone, such as protein-level overactivation.
Future research will focus on maturing overall survival data and exploring the molecular mechanisms driving responses in non-altered tumors. Additionally, as CDK4/6 inhibitors become more widely used in the first-line setting in China, further studies will be needed to evaluate capivasertib's performance in patients who have received these prior therapies.
Summary updated